Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 6 January. Christopher Haig.

Executive Summary

Efemoral Medical believes its FlexStep bioabsorbable stent technology combines the best attributes of balloon-expandable and self-expandable stents to address difficult-to-treat peripheral artery disease. See what Efemoral’s CEO, Christopher Haig, said about the technology here.

“We’re not worried about trading off flexibility versus rigidity. We’re just optimizing for rigidity, because the flexibility will come from those inter-scaffold spaces.”– Christopher Haig, CEO, Efemoral

Click here for a free trial of Medtech Insight

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts